Objectives. The Scleroderma Patient-centered Intervention Network (SPIN) Cohort is a web-based cohort designed to collect patient-reported outcomes at regular intervals as a framework for conducting trials of psychosocial, educational, self-management and rehabilitation interventions for patients with SSc. The aim of this study was to present baseline demographic, medical and patient-reported outcome data of the SPIN Cohort and to compare it with other large SSc cohorts. Conclusion. Although there are some differences, the SPIN Cohort is broadly comparable with other large prevalent SSc cohorts, increasing confidence that insights gained from the SPIN Cohort should be generalizable, although it should be noted that all three cohorts include primarily White participants.
Introduction
Patients living with rare diseases often lack access to disease-specific psychosocial, educational, self-management and rehabilitation interventions that are important components of disease management and patient-centred care in more common diseases. In common chronic illnesses, evidence suggests that self-management strategies can positively impact disease-specific outcomes and quality of life [1, 2] . However, in the context of rare diseases like SSc or scleroderma, there is a lack of evidence to support disease-specific interventions. To address this problem, the Scleroderma Patient-centered Intervention Network (SPIN) was formed in 2011 as an international collaboration to develop and test self-management, educational, psychosocial and rehabilitation interventions for patients living with SSc [3] .
Recognizing that rare diseases present a major barrier to conducting adequately powered trials, SPIN utilizes the cohort multiple randomized controlled trial (cmRCT) design [4] . In this design, a cohort of patients is followed longitudinally and consented to participate in trials of online interventions. Upon enrolment, physicians provide basic medical data, and patients complete a core set of patient-reported outcome measures every 3 months [3] .
The objectives of this study were to summarize baseline demographic and clinical characteristics of participants in the SPIN Cohort and to compare these baseline data with that of two other large SSc cohorts with similar published data, the Canadian Scleroderma Research Group (CSRG) Registry and the European Scleroderma Trials and Research (EUSTAR) group cohort, in order to determine similarities or differences between these cohorts that could affect the generalizability of SPIN findings.
Methods

SPIN Cohort
This study includes baseline data of patients enrolled in the SPIN Cohort who completed study questionnaires from April 2014 through October 2016. Patients included in the study were enrolled at 32 centres in Canada, the USA, the UK and France. Eligible patients must be classified by a SPIN physician as having SSc according to the 2013 ACR/EULAR classification criteria [5] ; be at least 18 years of age; and be able to provide consent and complete questionnaires online in English or French. The SPIN sample is a convenience sample. The attending physician or nurse coordinator invites eligible patients, obtains informed consent and completes a medical data form that is submitted online to initiate patient registration. Cohort patients complete patient-reported outcome measures online upon enrolment and subsequently every 3 months. The SPIN Cohort study was approved by the Research Ethics Committee of the Jewish General Hospital, Montreal, Canada and by the Institutional Review Boards of participating centres [3] . This approval covered the present study and no additional ethical approval was required.
Comparison cohorts: CSRG and EUSTAR
A detailed description of inclusion and exclusion criteria and recruitment procedures for the CSRG and EUSTAR cohorts can be found elsewhere [6, 7] .
In short, patients in the CSRG cohort were enrolled be- [6, 8] .
Measures
Sociodemographic and medical data
For the SPIN Cohort, patients provided demographic data. SPIN physicians completed a medical data form including all items of the 2013 ACR/EULAR SSc classification criteria [5] , as well as variables that were deemed to be important by SPIN rheumatologists (see SPIN cohort medical variables in the supplementary data, available at Rheumatology online).
Cochin Hand Function Scale
The 18-item Cochin Hand Function scale [9] measures the ability to perform daily hand-related activities. Items are scored on a scale from 0 (yes, without difficulty) to 5 (impossible). Total scores range from 0 to 90, and higher scores indicate more hand disability. The Cochin Hand Function scale has been validated in SSc [10] .
HAQ-Disability Index
Functional disability was measured using the HAQ-Disability Index (HAQ-DI) [11] . Items are rated on a 4-point scale, ranging from 0 (without any difficulty) to 3 (unable to do). The total score is the mean of the highest scores for each of the eight categories, with higher scores indicating greater functional disability. The HAQ-DI has been validated in SSc [11] . Numerical rating scales measured SSc-related functional disability due to RP, finger ulcers, breathing problems, gastrointestinal problems, pain and overall SSc, anchored between 0 (did not limit activities) to 10 (very severe limitation).
Patient Health Questionnaire-8
Symptoms of depression were measured using the Patient Health Questionnaire-8 (PHQ-8) [12] . Items are rated on a 4-point scale, ranging from 0 (not at all) to 3 (nearly every day). A total score is obtained by summing item scores, with higher scores indicating more depressive symptoms. The PHQ-8 performs equivalently to the PHQ-9 [13] , which is a validated measure of depressive symptoms in patients with SSc [14] .
Patient-Reported Outcomes Measurement Information System-29
The Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29v2) [15] measures eight domains of health status over the past 7 days. Items are scored on a 5-point scale, except for the item measuring pain intensity, which uses an 11-point rating scale. Higher scores represent more of the domain being measured (i.e. better physical function and ability to participate in social roles and activities; higher levels of anxiety, depression, fatigue, sleep disturbance, pain interference and pain intensity). Summed raw scores for each domain are converted into t-scores standardized from the general US population [mean (S.D.) = 50 (10)]. The PROMIS-29v2 has been validated in patients with SSc [16] .
Satisfaction With Appearance Scale
Body image concerns due to changes in appearance from SSc were assessed with the 14-item Satisfaction With Appearance Scale [17, 18] . Items are scored on a 7-point scale ranging from 1 (strongly disagree) to 7 (strongly agree). The Satisfaction With Appearance has two subscales, Perceived Social Impact, reflecting social discomfort, and Subjective Dissatisfaction, reflecting dissatisfaction with various body parts. Higher scores indicate greater body image dissatisfaction.
Self-Efficacy to Manage Chronic Disease Scale
The 6-item Self-Efficacy to Manage Chronic Disease Scale measures confidence in one's ability to manage disease symptoms as well as to reduce the need for medical care and reliance on medications [19] . Items are rated on a 10-point rating scale ranging from 1 (not confident at all) to 10 (totally confident). The score for the scale is the mean of all items, with higher scores reflecting greater self-efficacy. The Self-Efficacy to Manage Chronic Disease scale has been validated in patients with SSc [20] .
Statistical analyses
Descriptive statistics were used to summarize SPIN Cohort characteristics [means (S.D.) for continuous variables; frequency and proportions for categorical variables]. SPIN Cohort characteristics were compared with the EUSTAR and CSRG cohorts, using published baseline data [6, 7] . Available data were extracted from the publications and, where possible, compared with the SPIN Cohort. Continuous variables were compared using a t test, and categorical variables were compared using a Chi-square or Fisher exact test. Statistical significance was set at P < 0.05. The analyses were performed with the statistical software Stata version 14.2.
Results
Characteristics of the SPIN Cohort
Baseline demographic, clinical and patient-reported outcome data of the 1125 SPIN Cohort patients included in the analyses are presented in Table 1 . There were 460 (41%) participants classified as dcSSc. Mean (S.D.) age was 55.6 years (12.1), and most patients were female (87%) and White (82%).
Comparison of SPIN Cohort and CSRG
A comparison of the SPIN and CSRG cohorts by subgroups is presented in Table 2 . Scl70 antibodies were more frequent in both subsets in SPIN compared with CSRG. Skin involvement, sclerodactyly and ulcers were more frequent in CSRG than in SPIN in both subsets, and there were more pitting scars in the lsSSc group. Abnormal nailfold capillaries, on the other hand, were more frequent in SPIN than in CSRG in both subsets, and there were no differences with respect to the presence of telangiectasia. In regard to other organ involvement, there was a higher occurrence of oesophageal involvement in SPIN compared with in CSRG. Among dcSSc patients, SPIN patients experienced more interstitial lung disease compared with CSRG patients. The frequency of pulmonary arterial hypertension and SSc renal crisis were similar between the cohorts.
Comparison of SPIN cohort and EUSTAR
A comparison of baseline features between the SPIN and EUSTAR cohorts is presented in Table 2 . For both subsets, the frequency of the Scl 70 antibody was lower in SPIN compared with in EUSTAR (dcSSc 32% vs 60%; lcSSc 19% vs 23%). RNA polymerase 3 was higher in the SPIN subset than in EUSTAR (dcSSc: 41 vs 5%, lcSSc: 5 vs 1%), however, there was a high proportion of missing data in EUSTAR. There was a higher frequency of pitting scars in the SPIN dcSSc subset compared with EUSTAR dcSSc subset, and distal pulp ulcers were more frequent in both subsets of SPIN. Abnormal nailfold capillaries, on the other hand, were less frequent in SPIN than in EUSTAR. Oesophageal involvement was more frequent in SPIN compared with in EUSTAR. A direct comparison of interstitial lung disease and pulmonary arterial hypertension (PAH) could not be made, due to methodological differences in the measurement of these variables.
Discussion
The results of our study suggest that the SPIN Cohort has many similarities with the EUSTAR and CSRG cohorts. Methodological differences in the definition of organspecific involvement, as well as differences in data collection and the underlying rationale for establishing the cohort could explain some of the dissimilarities that were identified. The purpose of the SPIN project is to conduct rigorous trials on interventions to improve healthrelated quality of life and disability. Clinical data were collected to confirm the diagnosis of SSc and to provide a disease profile in terms of presence or absence of organ involvement at the time of enrolment. Both the CSRG and the EUSTAR cohorts, on the other hand, were developed specifically to follow disease progression over time.
With respect to organ involvement and antibody profiles it is uncertain whether the differences between cohorts are clinically significant or due to differences in methodology. For instance, for the definition of PAH, EUSTAR used the 2009 European Society of Cardiology/ European Respiratory Society (ESC/ERS) guidelines, while CSRG used echocardiographic measurement of pulmonary artery systolic pressure of >45 mmHg, and SPIN used the criterion ''according to standard definitions'' without specific testing criteria.
Since the purpose of this study was to compare SPIN Cohort characteristics with those of other SSc cohorts, we reported only the presence of clinical variables. Of note, the mere presence of a manifestation does not equate clinical impact or symptom burden from a patient's perspective. Future studies should assess the complex interplay of clinical characteristics and their impact on quality of life. The present study has limitations that should be considered in interpreting results. First, as both the SPIN Cohort and the CSRG Registry enrol patients from Canada, there is potential overlap between the participants in both cohorts. Overall, 26% of SPIN Cohort participants were enrolled from Candian centres, indicating the maximum possible overlap between SPIN and the CSRG. As published summary data were used to compare the cohorts, data were not available to identify the exact overlap between the cohorts. Second, the timeframe of enrolment differed somewhat between the three cohorts. Third, the definitions of medical variables also differed somewhat between the cohorts, limiting the comparisons that can be made. Although additional measures of disease variables may have been available for CSRG and EUSTAR, we compared SPIN Cohort data with the most comprehensive published data on these cohorts [9, 10] . Additional analyses comparing geographical regions in more detail may be of interest, but were beyond the scope of the present paper. Fourth, the SPIN Cohort constitutes a convenience sample of SSc patients receiving treatment at a SPIN recruiting centre, and patients at these centres may differ from those in other settings. Finally, SSc patients in the SPIN Cohort complete questionnaires online, and participants may differ from patients without internet access, for instance, in terms of education, coping or ability for self-advocacy.
Overall, there are many similarities between the SPIN Cohort and the other large recently reported SSc cohorts. Therefore, data emerging from the SPIN Cohort should be generalizable to the broader population of SSc patients, although it should be noted that all three cohorts include primarily White participants. CSRG did not specify n when missing data were <10%. Calculations were based on total n when no % missing data was provided. 
